AVTR250117C14000
- 0.00
- 0.000.00%
Avantor Newsroom
Avantor Is Maintained at Outperform by Raymond James
Raymond James Maintains Avantor(AVTR.US) With Buy Rating, Cuts Target Price to $26
Express News | Avantor Inc : Raymond James Cuts Target Price to $26 From $29
Declining Stock and Decent Financials: Is The Market Wrong About Avantor, Inc. (NYSE:AVTR)?
(AVTR) - Analyzing Avantor's Short Interest
Avantor Faces 2025 Market Challenges, Advantages Diminish, UBS Says
UBS Downgrades Avantor to Neutral, Lowers Price Target to $25
Avantor Analyst Ratings
UBS Downgrades Avantor(AVTR.US) to Hold Rating, Cuts Target Price to $25
Bernstein Maintains Avantor(AVTR.US) With Hold Rating
Argosy Healthcare Partners Promotes Greg Mayer to Partner
RBC Capital Keeps Their Buy Rating on Avantor (AVTR)
Morgan Stanley Maintains Avantor(AVTR.US) With Buy Rating, Maintains Target Price $27
Bernstein Maintains Avantor(AVTR.US) With Hold Rating, Raises Target Price to $24.5
Express News | Avantor® to Report Fourth Quarter and Full Year 2024 Earnings on Friday, February 7, 2025
Avantor to Report Fourth Quarter and Full Year 2024 Earnings on Friday, February 7, 2025
Avantor Announces EVP Jim Bramwell's Upcoming Retirement
High Quality Cyclical Stocks According to Morgan Stanley
Fluctuations are expected to continue in the early days of Trump's presidency, with Citigroup favoring Medical, Financial, and other defensive Industries.
In the market volatility and uncertainty following Trump's inauguration, defensive industries such as Medical Care and finance are favored in the model portfolio created by Citigroup strategists.
Avantor to Participate in the 43rd Annual J.P. Morgan Healthcare Conference